← Asymchem Laboratories Tian Jin overview

Asymchem Laboratories Tian Jin vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Asymchem Laboratories Tian Jin Co Ltd (002821.CS)

Q3 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

August 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Latest
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

© 2026 MarketIVWhy